Anti-amnesic effects of Evolvulus alsinoides Linn. in amyloid β (25-35) induced neurodegeneration in mice

Pharmacologyonline

Volumn 1, Issue , 2009, Pages 70-80

  Hanish Singh, J C ^a   Muralidharan, P ^b   Narsimha Reddy, Y ^c   Sathesh Kumar, S ^a   Alagarsamy, V ^a  

^a MNR College of Pharmacy   (India)

^b C L BAID METHA COLLEGE OF PHARMACY   (India)

^c KAKATIYA UNIVERSITY   (India)

Author keywords

Acetylcholinesterase enzyme; Alzheimer's disease; Amnesia; Amyloid (25 35); Antioxidants; Intracerebroventricular injection

Indexed keywords

ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN[25-35]; ASCORBIC ACID; EVOLVULUS ALSINOIDES EXTRACT; GLUTATHIONE PEROXIDASE; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BEHAVIOR CHANGE; BRAIN CORTEX; COGNITIVE DEFECT; CONTROLLED STUDY; DEGENERATIVE DISEASE; DRUG DOSE COMPARISON; DRUG MECHANISM; ENZYME ACTIVITY; EVOLVULUS ALSINOIDES; EXPLORATORY BEHAVIOR; HIPPOCAMPUS; MALE; MAZE TEST; MEDICINAL PLANT; MOUSE; NERVE DEGENERATION; NONHUMAN; OPEN FIELD BEHAVIOR;

EID: 65449171958     PISSN: None     EISSN: 18278620     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Cummings BJ, Pike CJ, Shankle R, Cotman CW. Beta amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease. Neurobiol Aging. 1996; 17: 921-933.
2. Pike CJ, Burdick D, Walencewicz A, Glabe CG, Cotman CW. Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J Neuroscience. 1993; 13:1676-1687.
3. 2 and 4-hydroxynonenal mediate amyloid beta induced neuronal apoptosis by activating JNKs and p38MAPK. Expt Neurology. 2003; 180: 144-155.
4. Maurice T, Lockhart BP, Privat A. Amnesia induced in mice by centrally administered beta-amyloid peptides involves cholinergic dysfunction. Brain Res. 1996; 706: 181-193.
5. Geula C, Mesulam MM. Cholinergic systems and related neuropathological predilection patterns in Alzheimer disease. In: Terry RD, Katzman R, Bick KL. (Eds.), Alzheimer Disease. Raven press., New York, 1994; 263-291.
6. Atack JR, Perry EK, Bonham JR, Perry RH, Tomlinson BE, Blessed G, Fairbairn A. Molecular forms of acetylcholinesterase in senile dementia of Alzheimer's type: selective loss of the intermediate (10S) form. Neurosci Lett. 1983; 40: 199-204.
7. Kennedy1 BP, Ziegler MG, Alford M, Hansen LA, Thal LJ, Masliah E. Early and persistent alterations in prefrontal cortex MAO A and B in Alzheimer's disease. J. Neural Transm. 2003; 110: 789-801.
8. Alvarez A, Alarcon R, Opazo C, Campos EO, Munoz FJ, Calderon FH, Dajas F, Gentry MK, Doctor BP, De Mello FG, Inestrosa NC. Stable complexes involving acetylcholinesterase and amyloid-β peptide change the biochemical properties of the enzyme and increase the neurotoxicity of Alzheimer's fibrils. J Neurosci. 1998; 18: 3213-3223.
9. Xiongwei Z, Arun KR, Hyounggon L, Gemma C, Mark AS, George P. Oxidative stress signalling in Alzheimer's disease. Brain Res. 2004; 1000: 32-39.
10. Mecocci P, MacGarvey U, Beal MF. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann Neurol. 1994; 36: 747-751.
11. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, Jones PK, Ghanbari H, Wataya T, Shimohama S, Chiba S, Atwood CS, Petersen RB, Smith MA. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol. 2001; 60: 759-767.
12. Smith MA, Perry G, Richey PL, Sayre LM, Anderson VE, Beal MF, Kowall N. Oxidative damage in Alzheimer's disease. Nature. 1996; 382: 120-121.
13. Good PF, Werner P, Hsu A, Olanow CW, Perl DP. Evidence of neuronal oxidative damage in Alzheimer's disease. Am J Pathol. 1996; 149: 21-28.
14. Butterfield DA, Drake J, Pocernich C, Castegna A. Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol Med. 2001; 7: 548-554.
15. Sayre LM, Zelasko DA, Harris PL, Perry G, Salomon RG, Smith MA. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J Neurochem. 1997; 68: 2092-2097.
16. Dennis Selkoe J. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature, 1999; 399:Supp.
17. Auddy B, Ferreira M, Blasina F, Lafon L, Arredondo F, Dajas F, Tripathi PC, Seal T, Mukherjee B. Screening of antioxidant activity of three Indian medicinal plants, traditionally used for the management of neurodegenerative diseases. J E Pharmacology. 2003; 84: 131-138.
18. Ganju L, Karan D, Chanda S, Srivastava KK, Sawhney RC, Selvamurthy W, Immunomodulatory effects of agents of plant origin. Indian Biomedicine & Pharmacotherapy. 2003; 57(7): 296-300.
19. Siripurapu KB, Gupta P, Bhatia G, Maurya R, Nath C, Palit G . Adaptogenic and anti-amnesic properties of Evolvulus alsinoides in rodents. Pharmacol Bioche. Behav. 2005; 81: 424-432
20. Mukherjee PK, Kumar V, Houghton PJ. Screening of Indian medicinal plants for acetylcholinesterase inhibitory activity. Phytotherap Res. 2007; 21:1142-1145.
21. Laursen SE, Belknap JK. Intracerebroventricular injections in mice. Some methodological refinements. J Pharmacol Methods. 1986; 16: 355-357.
22. (25-35) induced cognitive deficits in mice. J E Pharmacology. 2006; 104: 144-148.
23. Maria RR, Ivan I, Maria CBR, Jose AZ, DB, Amelia TH. Effect of lyophilised Vaccinium berries on memory, anxiety and locomotion in adult rats. Pharmacological Research. 2005; 52: 457-462.
24. Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods. 1984; 11: 47-60.
25. Ellman GL, Courtney KD, Andres VJ, Featherstone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacology. 1961; 7: 88-95.
26. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin's phenol reagent. Journal of Biological Chemistry. 1951; 193: 265-275.
27. Marklund S, Marklund G. Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. European J Biochem. 1974; 47: 469-474.
28. Mohandas J, Marshall JJ, Duggin GG, Horvath JS, Tiller D. Differential distribution of glutathione and glutathione related enzymes in rabbit kidney: possible implications in analgesic neuropathy. Cancer Research. 1984; 44: 5086-5091.
29. Oyama ST, Turnbull JD, Sauberlich HE. Selection and methods for the determination of ascorbic acid in animal tissue and fluid. Methods Enzymology. 1979; 62: 1-11.
30. Fibiger HC. Central cholinergic systems and memory. In: Squire LR, Lindenlaub E, editors. The Biology of Memory, Symposia Medica, Hoechst. New York' Springer-Verlag. 1990; 35-47.
31. Atsumi N, Akio I, Takaaki H, Toshitaka N. β -Amyloid protein-induced Alzheimer's disease animal model. Neurosci letters. 1994; 170: 63-66.
32. Casanova MF, Walker LC, Whitehouse PJ, Price DL. Abnormalities of the nucleus basalis in Down's syndrome. Ann Neurol. 1985; 18: 310-313.
33. Alvarez A, Opazo C, Alarcon R, Garrido J, Inestrosa NC. Acetylcholinesterase promotes the aggregation of amyloid-β peptide fragments by forming a complex with growing fibrils. J Mol Biol. 1997; 272: 348-361.
34. (1-42) impairs endogenous antioxidant systems in vivo. Neuroscience. 2003; 119: 399-419.
35. Hayes JD, Flanagan JU, Jowsey IR. Glutathione transferases. Annu. Rev Pharmaco. Toxicol. 2005; 45: 51-88.
36. Zandi P. Reduced risk of AD in uses of antioxidant vitamin supplements. Archives of neurology. 2004; 61: 82-88.
37. Ekinci FJ, Linsley MD, Shea TB. β amyloid induced calcium influx induces apoptosis in culture by oxidative stress rather than tau phosphorylation. Mol Brain Res. 2000; 76: 389-395.